Cited by 198Prostate Cancer Treatment and ResearchHormonal and reproductive studiesAdrenal Hormones and Disorders

11β-Hydroxydihydrotestosterone and 11-ketodihydrotestosterone, novel C19 steroids with androgenic activity: A putative role in castration resistant prostate cancer?

Storbeck, Karl-Heinz, Bloem, Liezl M., Africander, Donita, Schloms, Lindie, Swart, Pieter, Swart, Amanda C.·2013·Molecular and Cellular Endocrinology

Abstract

Adrenal C19 steroids, dehydroepiandrostenedione (DHEA(S)) and androstenedione (A4), play a critical role in castration resistant prostate cancer (CRPC) as they are metabolised to dihydrotestosterone (DHT), via testosterone (T), or via the alternate 5α-dione pathway, bypassing T. Adrenal 11OHA4 metabolism in CRPC is, however, unknown. We present a novel pathway for 11OHA4 metabolism in CRPC leading to the production of 11ketoT (11KT) and novel 5α-reduced C19 steroids - 11OH-5α-androstanedione, 11keto-5α-androstanedione, 11OHDHT and 11ketoDHT (11KDHT). The pathway was validated in the androgen-dependent prostate cancer cell line, LNCaP. Androgen receptor (AR) transactivation studies showed that while 11KT and 11OHDHT act as a partial AR agonists, 11KDHT is a full AR agonist exhibiting similar activity to DHT at 1nM. Our data demonstrates that, while 11OHA4 has negligible androgenic activity, its metabolism to 11KT and 11KDHT yields androgenic compounds which may be implicated, together with A4 and DHEA(S), in driving CRPC in the absence of testicular T.

Integrity signals

Registry

Crossref · 10.1016/j.mce.2013.07.006

Cites

56 of 56 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • 11KT is a substrate for 5α-reductases.

    “Furthermore, similar to the conversion of T to dihydrotestosterone (DHT) in target tissues, 11KT is a substrate for 5α-reductases (28).”
  • 11ketotestosterone and 11-keto-DHT bind and activate the androgen receptor.

    “including, 11ketotestosterone and 11-keto-DHT, androgens that bind and activate the androgen receptor.128,129”

    From Congenital adrenal hyperplasia (2017) · cites this paper as [129]

  • Activation/inactivation of glucocorticoids and 11-oxygenated androgens work in antiparallel manner, with 11β-hydroxy derivative being active glucocorticoid, while 11-keto androgens are more potent than their 11β-hydroxy counterparts.

    “Interestingly, activation/inactivation of glucocorticoids and 11-oxygenated androgens work in an antiparallel manner, with the 11β-hydroxy derivative being the active glucocorticoid [74,75], while the 11-keto androgens are more potent than their 11β-hydroxy counterparts [76].”
  • 11KT and 11KDHT are full AR agonists with the same AR activating potential as T and DHT, respectively.

    “While 11OHT and 11OHDHT represent partial AR agonists, 11KT and 11KDHT are full agonists with the same AR activating potential as T and DHT, respectively (Pretorius et al., 2016, Storbeck et al., 2013).”

    From Intracrine androgen biosynthesis, metabolism and action revisited (2018) · cites this paper as Storbeck et al., 2013

  • The expression of HSD11B2 is required for the activation of 11OHA4, which is the primary 11-oxygenated C19 androgen precursor in circulation.

    “It should also be noted that the expression of HSD11B2, which encodes the oxidative HSD11B isoform, is required for the activation of 11OHA4, which is the primary 11-oxygenated C19 androgen precursor in circulation (Rege et al., 2013, Storbeck et al., 2013, Swart et al., 2013) (Table 2).”

    From Intracrine androgen biosynthesis, metabolism and action revisited (2018) · cites this paper as Storbeck et al., 2013

Cites

Flagged first, then by citations

2 of the 58 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Storbeck, K.-H., Bloem, L. M., Africander, D., Schloms, L., Swart, P., & Swart, A. C.
Affiliations
Stellenbosch University (ZA)
Corresponding author
Swart, Amanda C.
Venue
Molecular and Cellular Endocrinology
Publisher
Elsevier BV
Published
2013-09
Volume
377
Issue
1-2
Pages
135-146
ISSN
0303-7207 (ISSN-L)
OpenAlex
W2171708792
Cited by
198
References
58
Citations by year
2026: 11 · 2025: 14 · 2024: 20 · 2023: 19 · 2022: 14 · 2021: 26 · 2020: 15 · 2019: 23 · 2018: 13 · 2017: 19 · 2016: 11 · 2015: 3 · 2014: 7 · 2013: 2
FWCI
6.24
Type
journal article
Language
en
Open access
closed
Locations
  • Molecular and Cellular Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Research Foundation of South Africa (THRIP TP2011060100001)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
Keywords
C19 steroids, castration-resistant prostate cancer, adrenal steroid metabolism, androstenedione, dehydroepiandrosterone, androgen receptor transactivation, 5α-reduced steroids, androgen production
MeSH terms
Aldo-Keto Reductase Family 1 Member C3, Androgens, Androstenedione, Animals, Chromatography, High Pressure Liquid, Estradiol Dehydrogenases, Humans, Hydroxyprostaglandin Dehydrogenases, Hydroxytestosterones, Male, Membrane Proteins, Molecular Weight, Receptors, Androgen, Mass Spectrometry, Testosterone, 3-Oxo-5-alpha-Steroid 4-Dehydrogenase, Transfection, 3-Hydroxysteroid Dehydrogenases, Transcriptional Activation, 11-beta-Hydroxysteroid Dehydrogenase Type 1, Cell Line, Tumor, Biosynthetic Pathways, Prostatic Neoplasms, Castration-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review